Outcomes
cerebral infarction
CEREBRAL INFARCTION
The primary outcome was C5a concentration in CSF on day 3 after ictus. We chose C5a as the primary outcome instead of free C5 because the primary target of this study was the anaphylatoxin C5a and not the membrane attack complex (C5b-9). Secondary outcomes were safety until 4 weeks after ictus, inflammatory parameters and eculizumab concentration in serum on day 1, 2, 4, 6, 9, 12, and 14 and CSF on day 3 after ictus, clinical condition measured by the NIHSS and WFNS score and any cerebral infarction on MRI at 2 weeks after ictus, cognition (MoCA) and quality of life scores (EQ-5D-5L/ EQ-VAS) 10 weeks after ictus, and functional outcome as measured by the mRS score 13 weeks after ictus. Serum and CSF immunoassays are described the 